Status In progress
Process MTA
ID number 1224

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors Imaging Equipment (lutetium - 177)
Others Department for Health and Social Care
  NHS England
  Welsh Government
Patient carer groups The NET Patient Foundation
Professional groups Association of Cancer Physicians
  British Institute of Radiology
  British Nuclear Medicine Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Comparator companies Accord Healthcare (5-fluorouracil, doxorubicin) (CAU not returned, not participating)
  Allergan UK (doxorubicin) (CAU not returned, not participating)
  Janssen (doxorubicin) (CAU not returned, not participating)
  medac GmBH (5-fluorouracil, dacarbazine, doxorubicin, lomustine) (CAU not returned, not participating)
  Merck Sharp and Dohme (interferon alfa-2b) (CAU not returned, not participating)
  Novartis (everolimus)
  Pfizer (doxorubicin, sunitinib)
  Roche Products (interferon alfa) (CAU not returned, not participating)
  Teva Pharma (doxorubicin) (CAU not returned, not participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
12 June 2018 Committee meeting: 3
05 June 2018 Following the committee meeting on 11 April 2018, there were internal discussions and as a consequence we were unable to release the appraisal consultation document (ACD) for this appraisal. We have contacted clinical experts to clarify the issues identified during the development of the ACD. In addition, the company has requested to submit a new value proposition for lutetium. We will therefore not be issuing the ACD that was developed at this stage. The appraisal committee will consider this additional evidence and continue its deliberations on Tuesday 12 June 2018.
11 April 2018 Committee meeting: 2
20 February 2018 In September 2017 we informed you that the company had requested to submit additional clinical data at the appraisal consultation stage. This data is being reviewed by the Assessment Group and we are therefore able to schedule a further discussion of this at the technology appraisal committee meeting on 11 April 2018.
03 August 2017 - 24 August 2017 Appraisal consultation
20 June 2017 This technology appraisal was originally included in scope for ID858, however as NICE is unable to release any recommendations on 177Lu-dotatate until it has a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, this has been separated. The recommendations for everolimus and sunitinib can be found on the NICE website.
28 February 2017 Committee meeting: 1
25 May 2016 Invitation to participate
25 May 2016 In progress, Invitation to participate
04 November 2015 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance